Dr. Nuermberger’s primary research interest is the experimental chemotherapy of TB. The work uses validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new drugs and drug regimens. A major goal is to identify new agents that can be combined together in novel regimens or combined with existing drugs to shorten the duration of TB therapy. A newer interest is to develop improved animal models of non-tuberculous mycobacterial infection to enable a similar approach to drug and regimen development for these difficult-to-treat infections.